An excretion balance and pharmacokinetic study of the novel anticancer agent E7070 in cancer patients

Anti-Cancer Drugs

Volumn 13, Issue 8, 2002, Pages 807-814

  Van den Bongard, H J G Desirée ^a   Pluim, Dick ^a   Rosing, Hilde ^a   Nan Offeringa, Lianda ^a   Schot, Margaret ^a   Ravic, Miroslav ^a   Schellens, Jan H M ^a   Beijnen, Jos H ^a  

^a SLOTERVAART HOSPITAL   (Netherlands)

Author keywords

14C labeled E7070; Anticancer agent; Benzene disulfonamide derivative; Excretion; Pharmacokinetics

Indexed keywords

ANTINEOPLASTIC AGENT; INDISULAM; N (3 CHLORO 7 INDOLYL) 1,4 BENZENE DISULFONAMIDE; SULFONAMIDE; UNCLASSIFIED DRUG;

ADULT; AREA UNDER THE CURVE; ARTICLE; CANCER PATIENT; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG BLOOD LEVEL; DRUG EXCRETION; DRUG GLUCURONIDATION; DRUG STRUCTURE; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; LIQUID SCINTILLATION COUNTING; MALE; MASS SPECTROMETRY; PRIORITY JOURNAL; SOLID TUMOR;

ADULT; AGED; ANTINEOPLASTIC AGENTS; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; PROSPECTIVE STUDIES; SULFONAMIDES;

EID: 0036746940     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-200209000-00004     Document Type: Article

References (12)

1. Owa T, Okauchi T, Yoshimatsu K, et al. A focused compound library of novel N-(7-indolyl)benzenesulfonamides for the discovery of potent cell cycle inhibitors. Bioorg Meal Chem Lett 2000; 10: 1223-6
2. 1 phase of the cell cycle. J Med Chem 1999; 42: 3789-99
3. Maren TH. Relations between structure and biological activity of sulfonamides. Annu Rev Pharmacol Toxicol 1976; 16: 309-27
4. Yoshimatsu K, Yamaguchi A, Yoshino H, Koyanagi N, Kitoh K. Mechanism of action of E7010, an orally active sulfonamide antitumor agent: inhibition of mitosis by binding to the colchicine site of tubulin. Cancer Res 1997; 57: 3208-13
5. Yoshino H, Ueda N, Niijima J, et al. Novel sulfonamides as potential, systemically active antitumor agents. J Med Chem 1992; 35: 2496-7
6. Sherr JC. Cancer cell cycles. Science 1996; 274: 1672-7
7. Lundberg AS, Weinberg RA. Control of the cell cycle and apoptosis. Eur J Cancer 1999; 35: 1886-94
8. Ozawa Y, Sugi NH, Nagasu T, et al. E7070, a novel sulphonamide agent with potent antitumour activity in vitro and in vivo. Eur J Cancer 2001; 37: 2275-82
9. Raymond E, Fumoleau P, Roche H, et al. Combined results of 4 phase I and pharmacokinetic (PK) studies of E7070, a novel chloroindolyl-sulphonamide inhibiting the activation of cdk2 and cyclin E. Clin Cancer Res 2000; 40:384 (abstr)
10. Punt CJA, Fumoleau P, van de Walle B, Faber MN, Ravic M, Campone M. Phase I and pharmacokinetic study of E7070, a novel sulfonamide, given at a daily times five schedule in patients with solid tumours. A study by the EORTC-Early Clinical Studies Group (ECSG). Ann Oncol 2001; 12: 1289-93
11. van Kesteren C, Mathôt R, Raymond E, et al. Population pharmacokinetic analysis of the novel anti-cancer agent E7070 in three phase I studies using nonlinear mixed effect modelling (NONMEM). Proc Am Soc Clin Oncol 2001; 20: 93a (abstr)
12. Rosing H, Hillebrand MJX, Ravic M, Foley K, Schellens JHM, Beijnen JH. Determination of E7070 and its metabolite M1 in biological matrices using liquid chromatography coupled with electrospray ionization tandem mass spectrometry. In: 17th (Montreux) Symp Liquid Chromatography (LC/MS;SFC/MS;CE/MS;MS/MS) 2000; 101 (abstr)